Related Experiment Videos

Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease

C B Caputo¹, C W Scott, I R Sobel

¹ICI Pharmaceuticals Group, ICI Americas, Wilmington, DE.

Clinical Neuropharmacology

|January 1, 1992

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate.

The journal of prevention of Alzheimer's disease·2022

Reversible and Species-Specific Depigmentation Effects of AZD3293, a BACE Inhibitor for the Treatment of Alzheimer's Disease, Are Related to BACE2 Inhibition and Confined to Epidermis and Hair.

The journal of prevention of Alzheimer's disease·2017

Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer's disease and frontotemporal lobar degeneration.

Cellular and molecular life sciences : CMLS·2014

Loss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics.

Neuroscience letters·2002

Accumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer's disease.

Journal of chemical neuroanatomy·2001

Potent reversible inhibitors of the protein tyrosine phosphatase CD45.

Journal of medicinal chemistry·2001

See all related articles